Video Insights
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
Dr. Ryan Jacobs reviews the latest CLL data, highlighting time-limited regimens, BTK combos, and clinical trial updates.
Side effects are an important consideration when using bispecific antibodies in this population, Dr. Krina Patel explains.
The phase 3 SENTRY trial will randomize patients to ruxolitinib plus placebo or selinexor plus placebo.
Dr. Krina Patel was part of a comparative study team which evaluated these two therapies' efficacy and safety in MM care.
Robert Daly, MD discusses how symptom monitoring after discharge can reduce readmissions in cancer care.
Ruchi Desai, MD, specifies what improvements are needed today in the therapy options available for myelofibrosis.
Naval Daver, MD reviews new immunotherapy and targeted strategies transforming ALL treatment and outcomes.
Ruchi Desai, MD, speaks on the challenges of clinical evaluation and therapy optimization in myelofibrosis.
Dr. Sanam Loghavi outlines genetic testing, MRD monitoring, and evolving strategies in newly diagnosed CLL.
Dr. John Mascarenhas discussed novel type 2 JAK inhibitors for myelofibrosis, such as AJ1-11095 and INCB160058.
Our expert roundtable reacts to data presented at ASCO 2025 on real-world use of the agent in this setting.
Experts discuss what data do clinicians need in order to optimize their first-line use of this agent for low-risk MDS.
NKTR-255 plus liso-cel shows promise in boosting CD8+ CAR T cells and improving remission in R/R LBCL.
Our expert panel reacts to the updated efficacy and safety data for luspatercept presented at ASCO 2025.
Panelists discuss how these biomarkers factor into their therapy choices and the impact of new data from ASCO 2025.
New CAR T and bispecific therapies are reshaping myeloma care. Here's what the latest data reveals.
Manali Kamdar, MD, assesses the effect on clinical practice from these label updates for CD19- and BCMA-targeting therapies.
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
TAG shows promise for BPDCN patients under 50, reducing toxicity and enabling safer transplants.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.